Skip to content

Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood

The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01756209
Enrollment
160
Registered
2012-12-25
Start date
2010-01-31
Completion date
2012-02-29
Last updated
2020-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

Aim: The purpose of this study was to evaluate both the effects of ibuprofen and/or acetaminophen for the acute treatment of primary migraine in children in or out prophylactic treatment with magnesium. Methods: The study had been approved by the Researchers Ethics Committee of the Pugliese-Ciaccio Hospital (protocol number 720/2010; EUDRACT NUMBER 2012-005737-36) and the children ranging from the ages of 5 to 18 years with at least four attack/month of primary migraine were enrolled. A Visual Analogical Scale was used to evaluate pain intensity at the moment of admission to the study (start of the study) and every month up to 18 months later (end of the study).

Detailed description

Study design The present work is a single-blind, balanced recruitment, parallel-group, single center study in outpatient children enrolled at the Pediatric Unit-Pugliese Ciaccio Hospital in Catanzaro, Italy, between January 2010 and June 2010. This study had been approved by the Researchers Ethics Committee of the Pugliese-Ciaccio Hospital (protocol number 720/2010; EUDRACT NUMBER 2012-005737-36), and was conducted following the Declaration of Helsinki and the Guidelines for Good Clinical Practice criteria. Population Children with migraine without aura (MoA) of both sexes aged from 5 to 16 years, with at least four attacks /month, were eligible for the study. MoA was diagnosed according to the criteria for pediatric age of the International Classification of Headache Disorders (IHS-2) \[22\]. Exclusion criteria were the following: mental retardation (IQ \<70), genetic syndromes (e.g., Down syndrome, Prader-Willi syndrome, fragile X syndrome), hypothyroidism, psychiatric disorders (i.e.: schizophrenia, mood disorders, ADHD), neuromuscular disorders, epilepsy, obesity (BMI\>95 percentiles), liver or renal diseases, gastrointestinal disorders such as peptic or duodenal ulcer, dyspepsia, or heartburn; hypersensitivity to medication studies. Informed written consent was obtained by parents. Experimental protocol In a balanced recruitment study eligible outpatients with primary acute migraine were assigned to receive at pain onset: acetaminophen (15mg/kg) or ibuprofen (10mg/kg). Moreover, in order to evaluate the prophylaxis effect of magnesium in another set of experiments eligible children were assigned to receive a daily magnesium supplement (400 mg/daily) and then one single dose of acetaminophen (15mg/kg) or ibuprofen (10 mg/kg) at the time of pain (Figure 1). In this study, in agreement with the Declaration of Helsinki (1991), we did not use a placebo group. In each group, children were assigned in accordance to age, gender in order to obtain similar groups of treatment. In order to assess the intensity of pain, before and up to 3 hours after the administration of both drugs used in the present protocol, a non standardized ad hoc scale and a visual analogical scale (VAS) were used. Specifically, for the pre-dose assessments, the pain intensity was measured on an arbitrarily established categoric scales in response to the question, What is your pain level at this time? with response choices from 0 to 3, where 0 = none; 1 = mild; 2 = moderate; and 3 = severe. In addition, a visual analogical scale (VAS) was used to assess pain severity before, during and after the treatment. Patients were asked to draw a single vertical line on the 100-mm VAS, where 0 = no pain (score 0) and 100 mm = worst pain (score 10). This scale had been previously used to measure pain in pediatric populations . The safety on medication studies was assessed in terms of frequency and nature of adverse drug reactions (ADRs). In order to evaluate the association between ADRs and drug treatment, the Naranjo Adverse Probability Scale was applied . Number, duration, severity of pain attacks, analgesic intake and the occurrence of ADRs were recorded in a daily diary card 1 month prior to the trial and subsequently during the entire period of the study. For each patient, follow-up sessions were planned every month after enrollment and continued for 18 months (end of the study).

Interventions

magnesium 400 mg + conventional treatment

ibuprofen 10 mg/kg oral single dose

DRUGacetaminophen 15 mg/kg

Acetaminophen 15 mg/kg oral single dose

Sponsors

University of Catanzaro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children with migraine without aura (MoA) diagnosed according to the criteria for pediatric age of the International Classification of Headache Disorders (IHS-2) * aged from 5 to 18 years * at least four attacks /month

Exclusion criteria

* mental retardation (IQ \<70) * genetic syndromes (e.g., Down syndrome, Prader-Willi syndrome, fragile X syndrome) * hypothyroidism * psychiatric disorders (i.e.: schizophrenia, mood disorders, ADHD), * neuromuscular disorders, * epilepsy, * obesity (BMI\>95 percentiles), * liver or renal diseases, * gastrointestinal disorders such as peptic or duodenal ulcer, dyspepsia, or heartburn; * hypersensitivity to medication studies.

Design outcomes

Primary

MeasureTime frameDescription
Pain-relief3 and 18 monthsThe primary endpoint was when pain-relief took place and pain intensity differences from baseline (0 hour) to 3 hours after drug treatment. This measurement was defined as the AUC for the sum of the 2 measurements (pain relief and pain intensity difference) at each time point from 0 to 3 hours. Pain was measured using the vas analogue scale (range 0-10, where 0 = no pain (score 0) and 100 mm = worst pain (score 10)

Countries

Italy

Participant flow

Participants by arm

ArmCount
Acetaminophen
Acetaminophen 15 mg/kg oral single dose
40
Ibuprofen
Ibuprofen 10 mg/kg oral single dose
40
Mg + Acetaminophen
Magnesium 400 mg/daily + Acetaminophen 15 mg/kg oral single dose
40
Mg + Ibuprofen
Magnesium 400 mg/daily + Ibuprofen 10 mg/kg oral single dose
40
Total160

Baseline characteristics

CharacteristicAcetaminophenIbuprofenMg + AcetaminophenMg + IbuprofenTotal
Age, Categorical
<=18 years
40 Participants40 Participants40 Participants40 Participants160 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
pain visual analog scale (range 0 (better) -100 (worse) mm)6.95 units on a scale
STANDARD_DEVIATION 2.9
6.55 units on a scale
STANDARD_DEVIATION 2.85
7.57 units on a scale
STANDARD_DEVIATION 2.55
7.35 units on a scale
STANDARD_DEVIATION 2.93
7.11 units on a scale
STANDARD_DEVIATION 2.81
Region of Enrollment
Italy
40 participants40 participants40 participants40 participants160 participants
Sex: Female, Male
Female
20 Participants20 Participants20 Participants20 Participants80 Participants
Sex: Female, Male
Male
20 Participants20 Participants20 Participants20 Participants80 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 400 / 400 / 400 / 40
other
Total, other adverse events
0 / 400 / 400 / 400 / 40
serious
Total, serious adverse events
0 / 400 / 400 / 400 / 40

Outcome results

Primary

Pain-relief

The primary endpoint was when pain-relief took place and pain intensity differences from baseline (0 hour) to 3 hours after drug treatment. This measurement was defined as the AUC for the sum of the 2 measurements (pain relief and pain intensity difference) at each time point from 0 to 3 hours. Pain was measured using the vas analogue scale (range 0-10, where 0 = no pain (score 0) and 100 mm = worst pain (score 10)

Time frame: 3 and 18 months

ArmMeasureValue (MEAN)Dispersion
AcetaminophenPain-relief5.6 units on a scale*hrStandard Deviation 0.5
IbuprofenPain-relief5.1 units on a scale*hrStandard Deviation 0.6
Mg + AcetaminophenPain-relief2.25 units on a scale*hrStandard Deviation 0.3
Mg + IbuprofenPain-relief2.2 units on a scale*hrStandard Deviation 0.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026